MX2015012199A - Composiciones de cisplatino liposomal para la terapia contra el cancer. - Google Patents

Composiciones de cisplatino liposomal para la terapia contra el cancer.

Info

Publication number
MX2015012199A
MX2015012199A MX2015012199A MX2015012199A MX2015012199A MX 2015012199 A MX2015012199 A MX 2015012199A MX 2015012199 A MX2015012199 A MX 2015012199A MX 2015012199 A MX2015012199 A MX 2015012199A MX 2015012199 A MX2015012199 A MX 2015012199A
Authority
MX
Mexico
Prior art keywords
cisplatin
cancer therapy
mol
liposomal cisplatin
lipid
Prior art date
Application number
MX2015012199A
Other languages
English (en)
Spanish (es)
Inventor
William Mcghee
Original Assignee
Mallinckrodt Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Llc filed Critical Mallinckrodt Llc
Publication of MX2015012199A publication Critical patent/MX2015012199A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277Preparation processes; Proliposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
MX2015012199A 2013-03-13 2014-03-13 Composiciones de cisplatino liposomal para la terapia contra el cancer. MX2015012199A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361780272P 2013-03-13 2013-03-13
PCT/US2014/026341 WO2014160337A1 (en) 2013-03-13 2014-03-13 Liposomal cisplatin compositions for cancer therapy

Publications (1)

Publication Number Publication Date
MX2015012199A true MX2015012199A (es) 2015-11-30

Family

ID=50439522

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012199A MX2015012199A (es) 2013-03-13 2014-03-13 Composiciones de cisplatino liposomal para la terapia contra el cancer.

Country Status (8)

Country Link
US (2) US10039716B2 (enExample)
EP (1) EP2968142A1 (enExample)
JP (1) JP6077710B2 (enExample)
CN (1) CN105209017A (enExample)
BR (1) BR112015022415A2 (enExample)
CA (1) CA2903254C (enExample)
MX (1) MX2015012199A (enExample)
WO (1) WO2014160337A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5994049B2 (ja) * 2012-10-01 2016-09-21 兵神装備株式会社 吐出システム
WO2016141161A1 (en) * 2015-03-03 2016-09-09 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
WO2016141167A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Combination liposomal pharmaceutical formulations
US20170049701A1 (en) * 2015-08-05 2017-02-23 Steven M. Kushner Clustoidal multilamellar soy lecithin phospholipid structures for transdermal, transmucosal, or oral delivery, improved intestinal absorption, and improved bioavailability of nutrients
WO2017053464A1 (en) * 2015-09-21 2017-03-30 Mallinckrodt Llc Improved stability of liposome formulations and uses thereof
PE20181445A1 (es) * 2016-01-07 2018-09-12 Univ Western Health Sciences Formulaciones para el tratamiento del cancer de vejiga
WO2017142876A1 (en) 2016-02-15 2017-08-24 University Of Georgia Research Foundation, Inc. lPA-3-LOADED LIPOSOMES AND METHODS OF USE THEREOF
AU2017268175B2 (en) 2016-05-16 2023-02-23 Access To Advanced Health Institute PEGylated liposomes and methods of use
SG10202107836SA (en) * 2017-01-18 2021-08-30 Temasek Life Sciences Laboratory Ltd Hyperstabilized liposomes increase targeting of mitotic cells
WO2019094648A1 (en) 2017-11-08 2019-05-16 L.E.A.F. Holdings Group Llc Platinum complexes and uses thereof
ES2998498T3 (en) 2020-03-10 2025-02-20 Univ Chung Yuan Christian Liposome composition and preparation method thereof
TW202345843A (zh) * 2022-04-06 2023-12-01 財團法人國家衛生研究院 脂質奈米顆粒及脂質體

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843473A (en) * 1989-10-20 1998-12-01 Sequus Pharmaceuticals, Inc. Method of treatment of infected tissues
US20020009488A1 (en) * 1995-05-03 2002-01-24 Polymasc Pharmaceuticals Plc Tissue entrapment
WO1998007409A1 (en) * 1996-08-23 1998-02-26 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
BR9815445A (pt) 1997-02-05 2001-09-25 Pharmacia & Upjohn Spa Complexos lipìdicos e lipossomas de complexos de platina altamente insolúveis
ES2236181T3 (es) 2000-01-28 2005-07-16 Alza Corporation Liposomas que contienen un compuesto atrapado en una solucion supersaturada.
WO2002036073A2 (en) * 2000-11-02 2002-05-10 Smithkline Beecham Corporation Receptor antagonist-lipid conjugates and delivery vehicles containing same
EP1448165B1 (en) * 2001-11-13 2007-09-19 Celator Pharmaceuticals, Inc. Lipid carrier compositions and methods for improved drug retention
EP1674081A1 (de) * 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
EP1716870A1 (en) * 2005-04-29 2006-11-02 Bracco Imaging S.p.A. MRI contrast agents endowed with concentration independent responsiveness
US20100034874A1 (en) 2006-12-08 2010-02-11 Katayama Chemical Industries Co., Ltd. Liposome encapsulating ammine-platinum complex at high concentration, and method for production of the liposome

Also Published As

Publication number Publication date
US20140271821A1 (en) 2014-09-18
WO2014160337A1 (en) 2014-10-02
US10039716B2 (en) 2018-08-07
US20180318219A1 (en) 2018-11-08
JP2016513651A (ja) 2016-05-16
CA2903254C (en) 2019-04-09
US10383823B2 (en) 2019-08-20
CA2903254A1 (en) 2014-10-02
EP2968142A1 (en) 2016-01-20
BR112015022415A2 (pt) 2017-07-18
CN105209017A (zh) 2015-12-30
JP6077710B2 (ja) 2017-02-08

Similar Documents

Publication Publication Date Title
MX2015012199A (es) Composiciones de cisplatino liposomal para la terapia contra el cancer.
MX2015012200A (es) Composiciones de oxaliplatino en liposomas para la terapia contra el cancer.
MX2015012201A (es) Formulaciones modificadas de liposomas de docetaxel.
NZ732777A (en) Ionizable cationic lipid for rna delivery
SG10201906075VA (en) Methods of treating cancer
MX2014004960A (es) Composiciones liposomales combinadas para terapia contra el cancer.
MX363455B (es) Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
MY160249A (en) Fatty acid fumarate derivatives and their uses
MX2021006723A (es) Formulacion para anticuerpo anti-a4b7.
IN2014DN05866A (enExample)
WO2013188847A8 (en) Compositions and methods for transmucosal absorption
MY168791A (en) Carbamate compounds and of making and using same
IN2014MN00948A (enExample)
WO2008070463A3 (en) Endoxifen methods and compositions
CA2882523C (en) Lipid assemblies comprising anionic lysolipids and use thereof
PH12015501239A1 (en) Oral care products comprising tetrabasic zinc chloride and trimethylglycine
NZ708821A (en) Lfa-1 inhibitor formulations
PL394082A1 (pl) Liposomowy preparat zawierający przeciwnowotworową substancję aktywną, sposób jego wytwarzania i zawierająca go kompozycja farmaceutyczna
MX360315B (es) Composiciones farmaceuticas que comprenden un inhibidor de aromatasa.
PH12013500251A1 (en) Oral care compositions
WO2011143271A3 (en) Therapeutic liposomes and methods for producing and using the same
GB201114230D0 (en) Addition copolymers and their use
MX2012007682A (es) Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
IN2015DN01223A (enExample)
WO2020018049A3 (en) Lipid nanoparticles loaded with ceranib-2 as anticancer agents